Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat

Br J Pharmacol. 2008 Sep;155(2):217-26. doi: 10.1038/bjp.2008.256. Epub 2008 Jun 23.

Abstract

Background and purpose: Experiments were designed to determine the modulation by nitric oxide (NO) and endothelium-dependent hyperpolarizations (EDHF-mediated responses) of endothelium-dependent contractions in renal arteries of normotensive and hypertensive rats.

Experimental approach: Rings, with or without endothelium, of renal arteries of 8-month-old Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were suspended in myographs for isometric force recording.

Key results: ACh evoked relaxations in preparations contracted with phenylephrine. L-NAME (inhibitor of NOS) attenuated (WKY) or abolished (SHR) these relaxations. TRAM-34 plus UCL 1684 (inhibitors of EDHF-mediated responses) did not decrease the relaxation, except in rings of WKY when L-NAME was also present. High concentrations of ACh caused a secondary increase in tension, augmented in rings of WKY by L-NAME or TRAM-34 plus UCL 1684. The increase in tension was prevented by indomethacin. Under baseline tension, ACh induced endothelium-dependent contractions, prevented by indomethacin (COX inhibitor) or terutroban (TP receptor antagonist). The calculated endothelium-dependent contractions were larger in rings of SHR compared with those of WKY. In preparations of SHR, the contractions were augmented by L-NAME in the presence of SC19220 (EP-1 receptor antagonist). In arteries of WKY, the endothelium-dependent contractions were augmented by TRAM-34 plus UCL 1684. The responses were reduced by SC19220.

Conclusions and implications: In the renal artery of the rat, EDCF-mediated contractions are augmented by hypertension. The endothelium-dependent contractions are facilitated by NOS inhibition (in the presence of an EP-1 receptor antagonist) and by the withdrawal of EDHF-mediated responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Animals
  • Biological Factors / deficiency*
  • Endothelium, Vascular / physiology
  • Endothelium, Vascular / physiopathology*
  • Hypertension / metabolism
  • Hypertension / physiopathology*
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Phenylephrine / pharmacology
  • Potassium / pharmacology
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WF
  • Rats, Inbred WKY
  • Receptors, Prostaglandin E / antagonists & inhibitors
  • Receptors, Prostaglandin E, EP1 Subtype
  • Renal Artery / physiopathology*
  • Vasoconstriction / physiology*

Substances

  • Biological Factors
  • Ptger1 protein, rat
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP1 Subtype
  • endothelium-dependent hyperpolarization factor
  • Phenylephrine
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Nitric Oxide Synthase Type III
  • Potassium